Myriad Genetics, Inc.
MYGN
$3.05
-$0.15-4.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 71.51% | -294.38% | -187.43% | -245.26% | -154.64% |
| Total Depreciation and Amortization | -14.77% | -13.52% | -12.25% | -9.11% | 8.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -88.26% | 351.73% | 198.12% | 586.25% | 514.88% |
| Change in Net Operating Assets | 135.41% | 66.45% | 64.52% | 41.40% | -29.78% |
| Cash from Operations | 134.07% | 137.50% | 120.69% | 96.86% | 75.65% |
| Capital Expenditure | 1.32% | 10.80% | 17.89% | 42.91% | 53.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -100.00% | -- |
| Other Investing Activities | 4.17% | -130.23% | -594.12% | -814.29% | -250.00% |
| Cash from Investing | -61.03% | -95.42% | -130.25% | -51.67% | 51.43% |
| Total Debt Issued | 56.25% | 25.00% | 37.50% | 32.14% | -33.33% |
| Total Debt Repaid | -0.17% | 25.00% | 32.64% | 28.77% | 50.17% |
| Issuance of Common Stock | -39.29% | -44.07% | -44.07% | -95.58% | -95.58% |
| Repurchase of Common Stock | 52.00% | 58.10% | 45.52% | 46.72% | 22.48% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,975.00% | -3,975.00% | -3,975.00% | -8,700.00% | -33.33% |
| Cash from Financing | 210.53% | 217.33% | 967.57% | -33.72% | -86.55% |
| Foreign Exchange rate Adjustments | -91.67% | 700.00% | 180.00% | -100.00% | 185.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 200.00% |
| Net Change in Cash | 289.14% | 643.48% | 235.86% | 81.45% | -52.17% |